- First presentation of preclinical data for newly-announced IL4I1 immuno-oncology program
- Additional data demonstrate potential of CD73 inhibitor CB-708 to combine with immuno-oncology and chemotherapy agents in solid tumors
“We look forward to sharing the first data on IL4I1, which is an investigational first-in-class small molecule immune-oncology program, as well as new data from the development program for our novel CD73 inhibitor CB-708,” said
IL4I1 (Interleukin 4-Induced Gene 1) is an enzyme that inhibits T-cell function. It is a novel target for cancer immunotherapy and aligns with Calithera’s clinical focus on onco-metabolism. Preclinical data from Calithera’s program exploring a novel, orally-bioavailable small-molecule inhibitor of IL4I1 will be presented in a
Date:
Title: Anti-tumor activity of a small molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1)
Presenter:
Location: Prince George’s
This presentation will include results from studies investigating the preclinical anti-tumor activity of an inhibitor of IL4I1. The compound dosed orally has demonstrated single-agent anti-tumor activity in B-cell lymphoma and other lymphoid and solid tumor mouse models, without observed toxicity in this setting. Additionally, it has demonstrated an ability to increase inflammation in tumors, consistent with an on-target mechanism of action.
An update on Calithera’s CB-708 program will be presented in a poster presentation (Abstract P484):
Date:
Title: CB-708, an orally bioavailable small molecule inhibitor of CD73 with immunostimulatory and anti-tumor activity
Presenter:
Location: Prince George's
CB-708 is an orally bioavailable, potent inhibitor of CD73, which in preclinical studies has demonstrated superior activity compared to a clinical CD73 antibody biosimilar. The
Additional meeting information and accepted abstracts can be found at the
About IL4I1
Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) is an enzyme that is primarily expressed by tumor cells and antigen presenting cells, and produces hydrogen peroxide, an inhibitor of T-cell function. IL4I1 has a potential role in immune evasion and inhibition may enhance an effective anti-tumor immune response. Calithera’s pipeline includes an investigational first-in-class, potent, orally-bioavailable IL4I1 inhibitor.
About CB-708
CB-708 is a small-molecule inhibitor of CD73, which is an enzyme in the tumor microenvironment that produces adenosine, a powerful inhibitor of immune function in tumors. CD73 is expressed across a wide range of tumor types and tumor infiltrating leukocytes. Expression of CD73 often correlates with poor prognosis in patients with cancer. Blockade of adenosine production by CD73 inhibition is expected to reverse immunosuppression in the tumor microenvironment and enhance the immune system’s ability to fight the cancer. CB-708 is orally bioavailable and shows distribution to all tissues, including the brain.
About Calithera
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera’s product candidates, the overall advancement of Calithera’s product candidates in clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's most recent Quarterly Report on Form 10-Q filed with the
SOURCE: Calithera Biosciences, Incorporated
CONTACT:
ir@Calithera.com
650-870-1071
Source: Calithera Biosciences, Inc.